Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This report describes the first known case of alopecia in a 16-year-old patient associated with quetiapine use, which resolved after stopping the medication.

This study observed some differences in clinical outcomes when comparing CPA with spironolactone, flutamide, and finasteride, but no differences with other therapies, possibly due to small study size and non-standardized assessments; adverse effects could not be fully compared across treatments.

This article discusses various manifestations and treatment methods for hyperandrogenism syndrome, particularly focusing on the effectiveness of systemic antiandrogenic therapy for severe or moderate hirsutism, and reports no new clinical results.

This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.

This study measured hyperkalemia rates in women using spironolactone for acne, hair loss, and hirsutism to evaluate the necessity of laboratory monitoring, examining variations among different age, racial, and ethnic groups.

In this study, researchers found that female rats exhibited more pronounced panic-related escape behavior during hypoxia, particularly in the diestrus phase, and that low-dose fluoxetine reduced this behavior, suggesting its potential for managing panic disorder symptoms related to hormonal cycles in women.

Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.

This study reports that spironolactone, a potassium-sparing diuretic with antiandrogenic activity, effectively improves hair density, reduces shedding, and stabilizes symptoms in female pattern hair loss, though symptoms often recur after discontinuation, suggesting the need for sustained therapy.

In this survey of dermatologists, pimozide was most commonly identified as the preferred first-line antipsychotic for treating delusions of parasitosis, followed by risperidone.

This study reported that extended-release valproate significantly reduced seizure frequency and improved quality of life in epilepsy patients over six months, despite some adverse effects like weight gain and tremor.

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

The researchers reported that metabolism of progesterone to 3α,5α-THP in the hippocampus is important for its antiseizure effects in ovariectomized rats.

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

This study reviewed 16 notable drug repurposing patent applications from 2025, highlighting potential new uses such as guanfacine for autonomic dysfunction and disulfiram for subarachnoid hemorrhage survival, though many disclosures lack peer-reviewed studies and no patents are granted.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This study concluded that alopecia is a rare side effect of SSRIs, with sertraline showing a higher association compared to citalopram, particularly among women.

This study provided the first published case reports of alopecia associated with the use of quetiapine.

This study demonstrated that GP derivatization improves mass spectral analysis of spironolactone and its metabolites by reducing in-source fragmentation and enhancing signal clarity, laying the groundwork for future advancements in reaction optimization and quantitative assay development.

In this review, spironolactone is highlighted for its emerging use in dermatology, particularly for treating androgen-mediated conditions like acne and hirsutism in susceptible females, though it requires careful monitoring for potential adverse effects.

This study found that sodium valproate significantly reduced seizure frequency by over 50% in about 70% of patients with generalized seizures but was less effective for partial seizures.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

This review compiles recent findings on the pharmacokinetics, pharmacodynamics, and pharmacogenomics of Valproate, highlighting potential new uses, benefits, and risks, but reports no new clinical results.